Comparison of first-line immunotherapy combinations for metastatic kidney cancer
This meta-analysis of first-line immunotherapy trials was published in the [...]
Re-treatment with immune checkpoint inhibitors in kidney cancer patients
Immune checkpoint inhibitor combinations for the treatment of patients with [...]
Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients
A study published in Clinical Genitourinary Cancer this month looks [...]
Bone metastases are associated with poor prognosis in papillary kidney cancer
A recent retrospective study looked at the data from 49 [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
First-line immunotherapy combination treatments for metastatic kidney cancer
A meta-analysis of four major clinical trials of immunotherapy combinations [...]
Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer
Results from a phase Ib/II study published in Journal of [...]
ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
New risk scoring system for metastatic kidney cancer
The treatment options for metastatic renal cell carcinoma (RCC) have [...]
Monitoring treatment toxicities in patients with renal cell carcinoma
Drs Dan George and Tian Zhang from the Duke Prostate [...]
